aDepartment of Pathology, Xianning Central Hospital, The First Affiliated Hospital of Hubei University of Science and Technology

bDepartment of Clinical Laboratory, Xianning Central Hospital, The First Affiliated Hospital of Hubei University of Science and Technology

cDepartment of Pathology, Chibi General Hospital, Xianning, China

Received 3 April 2022 Revised form accepted 25 April 2022

*Chengzhi Zhan and Hanyi Zhou contributed equally to the writing of this article.

Supplemental Digital Content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's website, www.anti-cancerdrugs.com.

Correspondence to Cheng Si, Department of Pathology, Chibi General Hospital, No. 260, Hebei Avenue, Chibi 437100, Xianning, Hubei Province, China, Tel: +86 0715 5369000; fax: +86 0715 5369000; e-mail: [email protected]